Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome

Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial

To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).

The investigators aim to investigate the efficacy of pregabalin in patients with irritable bowel syndrome (IBS), and to explore the etiology of IBS and the effective and rapid treatment for this etiology.

Inclusion Criteria:

1. Age range: 18-70 years old;
2. According to the Rome IV diagnostic criteria for IBS, the screening result is positive;
3. Mild to moderate IBS patients assessed based on the IBS-SSS.

Exclusion Criteria:

1. Concurrent gastrointestinal conditions presenting with symptoms potentially overlapping with those of IBS, significant medical comorbidities;
2. Severe mental disorders associated with marked personality disturbances, active suicidal thoughts or any self harm episodes within the preceding 12 months;
3. Current or intended pregnancy or lactation;
4. Cognitive impairment;
5. Recent use of pregabalin (within 30 days) or known allergy to pregabalin;
6. Concomitant use of medications that may interact with the study drug, mimic its effects, or aggravate expected adverse reactions (including but not limited to rosiglitazone, pioglitazone, opioids, anxiolytics, non opioid analgesics, mexiletine, dextromethorphan, and sedative hypnotics);
7. Use of IBS specific agents such as alosetron;
8. Consumption exceeding 50 units of alcohol weekly (where 1 unit corresponds to 10 mL of pure alcohol).